Status:

COMPLETED

Trial to Evaluate Steady State Pharmacokinetic Parameters, Efficacy and Safety of Nevirapine in Antiretroviral Drug naïve Pediatric Patients

Lead Sponsor:

Boehringer Ingelheim

Conditions:

HIV Infections

Eligibility:

All Genders

3-16 years

Phase:

PHASE2

Brief Summary

Trial to evaluate steady state pharmacokinetic parameters of nevirapine 150mg/m2 and nevirapine 4 or 7 mg/kg after 4 weeks, and efficacy and safety of the dosing when administered for 48 weeks in anti...

Detailed Description

A randomised open label multi-centre trial to evaluate the pharmacokinetic, efficacy and safety parameters of nevirapine 150mg/m2 and nevirapine 4 or 7mg/kg when administered in combination with ZDV a...

Eligibility Criteria

Inclusion

  • Inclusion:
  • Male or female patients between 3 months and 16 years of age at day 28 of the study.
  • Evidence of HIV-1 infection
  • Patients who are antiretroviral drug naive
  • Plasma viral load detectable
  • CD4 \>=50 cells/cc3
  • Written informed permission
  • Active assent given by the patient if the child is capable of understanding the given information
  • Reasonable probability for completion of the trial
  • Exclusion:
  • Any significant disease, other than HIV
  • Any acute illness within 2 weeks prior to Day 0
  • Patients requiring the continued use of inhibitors or inducers of P450 metabolic enzymes
  • Patients requiring systematic treatment with CYP3A4 substrates
  • Patients with malabsorption, severe chronic diarrhea
  • Receipt of any cytotoxic therapy for malignancy
  • Current grade 3 or 4 clinical or laboratory toxicity
  • Pregnancy or breast-feeding
  • Females of childbearing potential not using adequate contraception. allergy or known drug hypersensitivity to any of the study drugs intravenous drug abuse, alcohol or substance abuse

Exclusion

    Key Trial Info

    Start Date :

    January 1 2002

    Trial Type :

    INTERVENTIONAL

    End Date :

    December 1 2004

    Estimated Enrollment :

    123 Patients enrolled

    Trial Details

    Trial ID

    NCT00273975

    Start Date

    January 1 2002

    End Date

    December 1 2004

    Last Update

    October 31 2013

    Active Locations (4)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (4 locations)

    1

    Groote Schuur Hospital

    Cape Town, South Africa, 7900

    2

    Boehringer Ingelheim Investigational Site

    Pretoria, South Africa

    3

    Boehringer Ingelheim Investigational Site

    Soweto, South Africa, 2013

    4

    Boehringer Ingelheim Investigational Site

    Tygerberg, South Africa, 7505